Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report

Matthew J. Barth; Stanton Goldman; Lynette Smith; Sherrie Perkins; Bruce Shiramizu; Thomas G. Gross; Lauren Harrison; Warren Sanger; Mark B. Geyer; Lisa Giulino-Roth; Mitchell S. Cairo

doi:10.1111/bjh.12434

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report

Matthew J. Barth
, Stanton Goldman
, Lynette Smith
, Sherrie Perkins
, Bruce Shiramizu
, Thomas G. Gross
, Lauren Harrison
, Warren Sanger
, Mark B. Geyer
, Lisa Giulino-Roth
, Mitchell S. Cairo

Pediatrics

Medical City Children's Hospital
University of Nebraska Omaha
University of Utah
University of Hawai'i at Mānoa
Ohio State University
New York Medical College
University of Nebraska Medical Center
Massachusetts General Hospital
Cornell University
Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m²) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.

Original language	English
Pages (from-to)	678-683
Number of pages	6
Journal	British Journal of Haematology
Volume	162
Issue number	5
DOIs	https://doi.org/10.1111/bjh.12434
State	Published - Sep 2013

Keywords

CD20
Non-Hodgkin lymphoma
Pediatric
Pharmacokinetics
Rituximab

Access to Document

10.1111/bjh.12434

Cite this

Barth, M. J., Goldman, S., Smith, L., Perkins, S., Shiramizu, B., Gross, T. G., Harrison, L., Sanger, W., Geyer, M. B., Giulino-Roth, L., & Cairo, M. S. (2013). Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report. British Journal of Haematology, 162(5), 678-683. https://doi.org/10.1111/bjh.12434

@article{e764be4b2ea2490ab82f7197c214e7f2,

title = "Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report",

abstract = "The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.",

keywords = "CD20, Non-Hodgkin lymphoma, Pediatric, Pharmacokinetics, Rituximab",

author = "Barth, \{Matthew J.\} and Stanton Goldman and Lynette Smith and Sherrie Perkins and Bruce Shiramizu and Gross, \{Thomas G.\} and Lauren Harrison and Warren Sanger and Geyer, \{Mark B.\} and Lisa Giulino-Roth and Cairo, \{Mitchell S.\}",

year = "2013",

month = sep,

doi = "10.1111/bjh.12434",

language = "English",

volume = "162",

pages = "678--683",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc",

number = "5",

}

Barth, MJ, Goldman, S, Smith, L, Perkins, S, Shiramizu, B, Gross, TG, Harrison, L, Sanger, W, Geyer, MB, Giulino-Roth, L & Cairo, MS 2013, 'Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report', British Journal of Haematology, vol. 162, no. 5, pp. 678-683. https://doi.org/10.1111/bjh.12434

TY - JOUR

T1 - Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia

T2 - A Children's Oncology Group report

AU - Barth, Matthew J.

AU - Goldman, Stanton

AU - Smith, Lynette

AU - Perkins, Sherrie

AU - Shiramizu, Bruce

AU - Gross, Thomas G.

AU - Harrison, Lauren

AU - Sanger, Warren

AU - Geyer, Mark B.

AU - Giulino-Roth, Lisa

AU - Cairo, Mitchell S.

PY - 2013/9

Y1 - 2013/9

N2 - The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.

AB - The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.

KW - CD20

KW - Non-Hodgkin lymphoma

KW - Pediatric

KW - Pharmacokinetics

KW - Rituximab

UR - https://www.scopus.com/pages/publications/84881663487

U2 - 10.1111/bjh.12434

DO - 10.1111/bjh.12434

M3 - Article

C2 - 23802659

AN - SCOPUS:84881663487

SN - 0007-1048

VL - 162

SP - 678

EP - 683

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this